Data Analysis for 00-C-0154, A Randomized Phase II Study of a PSA-based Vaccine in Patients With Localized Prostate Cancer Receiving Standard Radiotherapy
- Evaluate the formation of antibody complexes in serum samples taken before initiation
of treatment and after completion of therapy in prostate cancer patients previously
enrolled on clinical trial NCI-00-C-0154.
- Evaluate immunologic response.
- Clone the underlying tumor antigens discovered through SEREX.
OUTLINE: Samples previously collected on clinical trial NCI-00-C-0154 (whole blood, serum,
and peripheral mononuclear blood cells) are analyzed for immunologic responses and evidence
of formation of anti-tumor antibodies. Western blot is used to detect any evidence of
vaccine-induced autoantibody responses. If there is an indication of response, SEREX is used
to clone the underlying antigens.
James Gulley, MD, PhD
National Cancer Institute (NCI)